Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Non-randomized Phase II Study of Anlotinib in Recurrent/Metastatic Head and Neck Adenocarcinomas

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT03591666
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:36:51.997824+00:00
Published At
2018-07-19T00:00:00+00:00
Record Updated At
2018-07-19
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Head and Neck Carcinoma", "Adenocarcinoma", "Recurrent Disease", "Distantly Metastatic Malignant Neoplasm"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2018-07-19"
protocolSection.identificationModule.nctId
"NCT03591666"
protocolSection.identificationModule.officialTitle
"A Non-randomized Phase II Study of Anlotinib in Recurrent/Metastatic Head and Neck Adenocarcinomas"
protocolSection.statusModule.overallStatus
"UNKNOWN"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Head and Neck Carcinoma (protocolSection.conditionsModule.conditions)
  • Adenocarcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Disease (protocolSection.conditionsModule.conditions)
  • Distantly Metastatic Malignant Neoplasm (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.